Inhibition of the second phase of amyloidogenesis in a mouse model by a single-dose colchicine regimen

Journal of Laboratory and Clinical Medicine

Volumn 138, Issue 2, 2001, Pages 107-111

  Shtrasburg, Shmuel ^a,b,c   Pras, Mordechai ^a,b,c   Gal, Rivka ^a,b,c   Salai, Moshe ^a,b,c   Livneh, Avi ^a,b,c  

^a HELLER INSTITUTE OF MEDICAL RESEARCH   (Israel)

^b HASHARON HOSPITAL   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034921116     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2001.116488     Document Type: Article

References (35)

1. Amyloidosis
2. The molecular basis of reactive amyloidosis
3. Secondary systemic amyloidosis: Response and survival in 64 patients
4. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils
5. Animal models for reactive amyloidosis
6. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever
7. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome
8. Blockage of amyloid induction by colchicine in an animal model
9. Colchicine inhibition of casein-induced amyloidosis in mice
10. Effect of colchicine on schistosoma-induced renal amyloidosis in Syrian golden hamsters
11. Animal model: Spontaneous and induced amyloidosis
12. Murine amyloid protein AA in casein-induced experimental amyloidosis
13. Biochemical evidence for the biphasic development of experimental amyloidosis
14. Kinetics of amyloid deposition. II. The effects of dimethylsulfoxide and colchicine therapy
15. Effect of colchicine on experimental amyloidosis in two CBA/J mouse models. Chronic inflammatory stimulation and administration of amyloid-enhancing factor during acute inflammation
16. The role of inflammatory cells in the pathogenesis of amyloidosis
17. Isolation and characterization of amyloid enhancing factor (AEF)
18. Extremely active murine amyloid enhancing factor
19. Colchicine inhibition of the first phase of amyloid synthesis in experimental animals
20. Long term effects of amyloid enhancing factor: Clinical and experimental implications
21. Pregnancy and amyloidogenesis: I. Offspring of amyloidotic mice are not predisposed to develop amyloidosis
22. Crush and smear technique for rapid detection and semiquantitation of amyloid deposition
23. Colchicine in acute inflammation: Stimulation of production of interleukin-1 and modulation of the acute phase serum amyloid A protein response
24. Ultrastructural evidence for the synthesis of serum amyloid A protein by murine hepatocytes
25. Colchicine inhibition of serum amyloid protein SAA and SAP synthesis in primary mouse liver cell cultures
26. Synthesis and secretion of serum amyloid protein A (SAA) by hepatocytes in mice treated with casein
27. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene
28. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine
29. Treatment of AL amyloidosis with melphalan, prednisone and colchicine
30. Survival of patients with primary (AL) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973)
31. Colchicine in the treatment of AA and AL amyloidosis
32. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only
33. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
34. Colchicine kinetics in patients with familial Mediterranean fever
35. Colchicine disposition in patients with familial Mediterranean fever with renal impairment